These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 35131966)

  • 41. Intraoperative imaging of metastatic lymph nodes using a fluorophore-conjugated antibody in a HER2/neu-expressing orthotopic breast cancer mouse model.
    Wu J; Ma R; Cao H; Wang Z; Jing C; Sun Y; Zhang Y; Yang Z; Hoffman RM; Tang J
    Anticancer Res; 2013 Feb; 33(2):419-24. PubMed ID: 23393332
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Construction of
    Guo X; Zhou N; Chen Z; Liu T; Xu X; Lei X; Shen L; Gao J; Yang Z; Zhu H
    Gastric Cancer; 2020 Jul; 23(4):614-626. PubMed ID: 31919745
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
    Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
    J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer.
    Jiang D; Im HJ; Sun H; Valdovinos HF; England CG; Ehlerding EB; Nickles RJ; Lee DS; Cho SY; Huang P; Cai W
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1296-1305. PubMed ID: 28265738
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.
    Kirpotin D; Park JW; Hong K; Zalipsky S; Li WL; Carter P; Benz CC; Papahadjopoulos D
    Biochemistry; 1997 Jan; 36(1):66-75. PubMed ID: 8993319
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A preliminary clinical trial to evaluate
    Lee I; Lim I; Byun BH; Kim BI; Choi CW; Woo SK; Kim KI; Lee KC; Kang JH; Seong MK; Kim HA; Noh WC; Lim SM
    EJNMMI Res; 2021 Jan; 11(1):8. PubMed ID: 33475899
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Preparation and preliminary bioevaluation studies of
    Suman SK; Kameswaran M; Pandey U; Sarma HD; Dash A
    J Labelled Comp Radiopharm; 2019 Oct; 62(12):850-859. PubMed ID: 31461549
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Gallium-67/68-Labeled Antibody Fragment for Immuno-SPECT/PET Shows Low Renal Radioactivity Without Loss of Tumor Uptake.
    Uehara T; Yokoyama M; Suzuki H; Hanaoka H; Arano Y
    Clin Cancer Res; 2018 Jul; 24(14):3309-3316. PubMed ID: 29666303
    [No Abstract]   [Full Text] [Related]  

  • 50. Site-Specific
    Yue TTC; Ge Y; Aprile FA; Ma MT; Pham TT; Long NJ
    Bioconjug Chem; 2023 Oct; 34(10):1802-1810. PubMed ID: 37751398
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase II Trial Assessing the Repeatability and Tumor Uptake of [
    Gondry O; Caveliers V; Xavier C; Raes L; Vanhoeij M; Verfaillie G; Fontaine C; Glorieus K; De Grève J; Joris S; Luyten I; Zwaenepoel K; Vandenbroucke F; Waelput W; Thyparambil S; Vaneycken I; Cousaert J; Bourgeois S; Devoogdt N; Goethals L; Everaert H; De Geeter F; Lahoutte T; Keyaerts M
    J Nucl Med; 2024 Feb; 65(2):178-184. PubMed ID: 38302159
    [TBL] [Abstract][Full Text] [Related]  

  • 52. (67/68)Ga-labeling agent that liberates (67/68)Ga-NOTA-methionine by lysosomal proteolysis of parental low molecular weight polypeptides to reduce renal radioactivity levels.
    Uehara T; Rokugawa T; Kinoshita M; Nemoto S; Fransisco Lazaro GG; Hanaoka H; Arano Y
    Bioconjug Chem; 2014 Nov; 25(11):2038-45. PubMed ID: 25303645
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Matching the decay half-life with the biological half-life: ImmunoPET imaging with (44)Sc-labeled cetuximab Fab fragment.
    Chakravarty R; Goel S; Valdovinos HF; Hernandez R; Hong H; Nickles RJ; Cai W
    Bioconjug Chem; 2014 Dec; 25(12):2197-204. PubMed ID: 25389697
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.
    Shah C; Miller TW; Wyatt SK; McKinley ET; Olivares MG; Sanchez V; Nolting DD; Buck JR; Zhao P; Ansari MS; Baldwin RM; Gore JC; Schiff R; Arteaga CL; Manning HC
    Clin Cancer Res; 2009 Jul; 15(14):4712-21. PubMed ID: 19584166
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
    Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
    Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples.
    Morgat C; Schollhammer R; Macgrogan G; Barthe N; Vélasco V; Vimont D; Cazeau AL; Fernandez P; Hindié E
    PLoS One; 2019; 14(1):e0210905. PubMed ID: 30645633
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PET Imaging of Abdominal Aortic Aneurysm with 64Cu-Labeled Anti-CD105 Antibody Fab Fragment.
    Shi S; Orbay H; Yang Y; Graves SA; Nayak TR; Hong H; Hernandez R; Luo H; Goel S; Theuer CP; Nickles RJ; Cai W
    J Nucl Med; 2015 Jun; 56(6):927-32. PubMed ID: 25883125
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.